| Dec'17 | Dec'16 | Dec'15 | ||||
|---|---|---|---|---|---|---|
Revenues | ||||||
789 | 165 | 162 | ||||
Research and development expenses | ||||||
5,106 | 6,115 | 3,904 | ||||
General and administrative expenses | ||||||
2,868 | 2,733 | 2,735 | ||||
Operating loss | ||||||
-7,185 | -8,683 | -6,477 | ||||
Other income | ||||||
769 | 0 | 0 | ||||
Finance expenses | ||||||
-621 | -55 | -133 | ||||
Finance income | ||||||
-633 | -374 | -106 | ||||
Total Financial income, net | ||||||
12 | 319 | -27 | ||||
Loss before taxes on income | ||||||
-6,404 | -8,364 | -6,504 | ||||
Taxes on income | ||||||
29 | 29 | 5 | ||||
Loss | ||||||
-6,433 | -8,393 | -6,509 | ||||
Amounts that will not be reclassified subsequently to profit or loss: | ||||||
Adjustment arising from translating financial statements from functional currency to presentation currency | ||||||
636 | 119 | -58 | ||||
Remeasurement loss from defined benefit plans | ||||||
0 | 0 | 99 | ||||
Total other comprehensive loss | ||||||
636 | 119 | -157 | ||||
Loss attributable to: | ||||||
Equity holders of the Company | ||||||
6,339 | 8,257 | 6,243 | ||||
Non-controlling interests | ||||||
94 | 136 | 266 | ||||
Loss | ||||||
-6,433 | -8,393 | -6,509 | ||||
Total comprehensive loss attributable to: | ||||||
Equity holders of the Company | ||||||
5,703 | 8,138 | 6,400 | ||||
Non-controlling interests | ||||||
94 | 136 | 266 | ||||
Total comprehensive loss | ||||||
-5,797 | -8,274 | -6,666 | ||||
Total comprehensive loss | ||||||
-5,797 | -8,274 | -6,666 | ||||
Loss per share attributable to equity holders of the Company: | ||||||
Basic and diluted loss per share | ||||||
0.19 | 0.30 | 0.27 | ||||